Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort.
Tumor molecular markers hold promise to distinguish potentially lethal from indolent prostate cancer and to guide treatment choices. A previous study identified a nine-gene molecular signature in tumors associated with prostate-specific antigen relapse after prostatectomy. We examined this molecular model in relation to prostate cancer death among 172 men with initially localized disease. We quantified protein expression of the nine genes in tumors to classify progression risk. Accounting for clinical prognostic factors, the nine-gene model did not provide discrimination to predict lethal and indolent prostate cancer.
Mucci
Lorelei A
LA
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA. lmucci@hsph.harvard.edu
Pawitan
Yudi
Y
Demichelis
Francesca
F
Fall
Katja
K
Stark
Jennifer R
JR
Adami
Hans-Olov
HO
Andersson
Swen-Olof
SO
Andrén
Ove
O
Eisenstein
Anna S
AS
Holmberg
Lars
L
Huang
Wei
W
Kantoff
Philip W
PW
Perner
Sven
S
Stampfer
Meir J
MJ
Johansson
Jan-Erik
JE
Rubin
Mark A
MA
D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015331:Cohort Studies; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000378:metabolism* / Q000401:mortality*; D015996:Survival Rate; D046888:Tissue Array Analysis
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen